Tenaya Therapeutics could earn up to $1.1B for new heart disease research
Tenaya Therapeutics and Alnylam Pharmaceuticals have agreed to collaborate on identifying potential new treatments for cardiovascular disease. Tenaya Therapeutics is a California-based biotechnology company focused on the development of new gene therapies for critical cardiovascular conditions. Alynylam Pharmaceuticals, meanwhile, is a Massachusetts-based biopharmaceutical company known for its work in RNAi therapeutics.
As a part of this new agreement between the two companies, Tenaya Therapeutics will validate up to 15 gene targets for Alnylam Pharmaceuticals in exchange for an upfront payment of $10 million. Tenaya Therapeutics could also earn additional payments for reaching various milestones—the total earnings could be as high as $1.13 billion.
“This multi-target collaboration underscores Tenaya’s commitment to rigorous science and capitalizes on the proprietary capabilities that have contributed to the discovery and development of Tenaya’s pipeline of candidates for cardiovascular conditions,” Faraz Ali, CEO of Tenaya Therapeutics, said in a prepared statement. “By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease.”
Tenaya Therapeutics has helped identify and validate more than 150 gene targets over the years. TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, are just two of the company’s success stories.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.